These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

629 related articles for article (PubMed ID: 33174384)

  • 1. Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis.
    Yates M; Mootoo A; Adas M; Bechman K; Rampes S; Patel V; Qureshi S; Cope AP; Norton S; Galloway JB
    Arthritis Rheumatol; 2021 May; 73(5):779-788. PubMed ID: 33174384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.
    Nash P; Kerschbaumer A; Dörner T; Dougados M; Fleischmann RM; Geissler K; McInnes I; Pope JE; van der Heijde D; Stoffer-Marx M; Takeuchi T; Trauner M; Winthrop KL; de Wit M; Aletaha D; Baraliakos X; Boehncke WH; Emery P; Isaacs JD; Kremer J; Lee EB; Maksymowych WP; Voshaar M; Tam LS; Tanaka Y; van den Bosch F; Westhovens R; Xavier R; Smolen JS
    Ann Rheum Dis; 2021 Jan; 80(1):71-87. PubMed ID: 33158881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
    Olivera PA; Lasa JS; Bonovas S; Danese S; Peyrin-Biroulet L
    Gastroenterology; 2020 May; 158(6):1554-1573.e12. PubMed ID: 31926171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib Versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study.
    Desai RJ; Pawar A; Weinblatt ME; Kim SC
    Arthritis Rheumatol; 2019 Jun; 71(6):892-900. PubMed ID: 30552833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of different Janus kinase inhibitors as monotherapy in rheumatoid arthritis: A Bayesian network meta-analysis.
    Qu B; Zhao F; Song Y; Zhao J; Yao Y; Chen Y; Liao R; Fu L
    PLoS One; 2024; 19(6):e0305621. PubMed ID: 38905267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK1 selective inhibitors for the treatment of spondyloarthropathies.
    White JPE; Coates LC
    Rheumatology (Oxford); 2021 May; 60(Suppl 2):ii39-ii44. PubMed ID: 33950224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis.
    Taylor PC; Weinblatt ME; Burmester GR; Rooney TP; Witt S; Walls CD; Issa M; Salinas CA; Saifan C; Zhang X; Cardoso A; González-Gay MA; Takeuchi T
    Arthritis Rheumatol; 2019 Jul; 71(7):1042-1055. PubMed ID: 30663869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
    Ho Lee Y; Gyu Song G
    J Clin Pharm Ther; 2020 Aug; 45(4):674-681. PubMed ID: 32495356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.
    Taylor PC; Takeuchi T; Burmester GR; Durez P; Smolen JS; Deberdt W; Issa M; Terres JR; Bello N; Winthrop KL
    Ann Rheum Dis; 2022 Mar; 81(3):335-343. PubMed ID: 34706874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review.
    Mori S; Ogata F; Tsunoda R
    Clin Rheumatol; 2021 Nov; 40(11):4457-4471. PubMed ID: 34554329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition.
    Dowty ME; Lin TH; Jesson MI; Hegen M; Martin DA; Katkade V; Menon S; Telliez JB
    Pharmacol Res Perspect; 2019 Dec; 7(6):e00537. PubMed ID: 31832202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: An analysis of postmarketing spontaneous safety reports.
    Goldman A; Galper BL; Druyan A; Grossman C; Sharif K; Shechtman L; Moshkovits Y; Lahat A; Ben-Zvi I
    Semin Arthritis Rheum; 2024 Aug; 67():152461. PubMed ID: 38772185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of Venous Thromboembolism Associated With Tofacitinib and Baricitinib: A Systematic Review and Indirect Meta-Analysis.
    Giménez Poderós T; Gallardo Borge S; Vazquez-Ferreiro P
    Pharmacotherapy; 2020 Dec; 40(12):1248-1264. PubMed ID: 33064892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse reactions to Janus kinase inhibitors: Study of their incidence and predictive factors in patients with rheumatoid arthritis.
    Martinez-Molina C; Guardiola Tey JM; Ruiz-Ramos J; Feliu A; Puig-Campmany M; Vidal S; Corominas H
    Med Clin (Barc); 2024 Oct; 163(8):391-396. PubMed ID: 39003114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
    Pope J; Sawant R; Tundia N; Du EX; Qi CZ; Song Y; Tang P; Betts KA
    Adv Ther; 2020 May; 37(5):2356-2372. PubMed ID: 32297280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cumulative incidence and risk of infection in patients with rheumatoid arthritis treated with janus kinase inhibitors: A systematic review and meta-analysis.
    Ouranos K; Avila DV; Mylona EK; Vassilopoulos A; Vassilopoulos S; Shehadeh F; Mylonakis E
    PLoS One; 2024; 19(7):e0306548. PubMed ID: 39083492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis.
    Bechman K; Subesinghe S; Norton S; Atzeni F; Galli M; Cope AP; Winthrop KL; Galloway JB
    Rheumatology (Oxford); 2019 Oct; 58(10):1755-1766. PubMed ID: 30982883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-Term Cardiovascular Complications in Dermatology Patients Receiving JAK-STAT Inhibitors: A Meta-Analysis of Randomized Clinical Trials.
    Ireland PA; Jansson N; Spencer SKR; Braden J; Sebaratnam D
    JAMA Dermatol; 2024 Mar; 160(3):281-289. PubMed ID: 38294793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Risk of Incident Venous Thromboembolism With Atopic Dermatitis and Treatment With Janus Kinase Inhibitors: A Systematic Review and Meta-analysis.
    Chen TL; Lee LL; Huang HK; Chen LY; Loh CH; Chi CC
    JAMA Dermatol; 2022 Nov; 158(11):1254-1261. PubMed ID: 36001310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel treatment for psoriatic arthritis: Janus kinase inhibitors.
    Chen M; Dai SM
    Chin Med J (Engl); 2020 Apr; 133(8):959-967. PubMed ID: 32209886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.